Predominant Expression of Interleukin-17 in Chronic Alopecia Areata Compared to IFN-γ in Pathogenic Th17 Cells, Tissue-Resident Memory T Cells and Natural Killer Cells

A user with alopecia totalis, borderline universalis, seeks advice on getting into a Xeljanz trial or appealing insurance for coverage. They experienced significant hair regrowth but are now seeing hair loss again and want to try Xeljanz.

A 35-year-old with alopecia areata has tried finasteride, topical and oral minoxidil, and dutasteride without success in stopping hair loss. The dermatologist suggests JAK inhibitors, but they are too costly, leading to uncertainty about the cause of hair loss.

Balding scalps have more androgen receptors, leading to increased TGF-beta, which causes blood vessel loss and hair follicle miniaturization. Blocking androgen signaling and TGF-beta may help prevent hair loss.

The user is experiencing diffuse thinning and inflammation despite using 2.5mg dutasteride daily, ciclopirox, and ketoconazole shampoos. They are considering treatments like hydroxychloroquine and JAK inhibitors due to suspected scarring alopecia and have faced challenges in obtaining a scalp biopsy.

The user is undergoing treatment for hair loss using finasteride, Kenalog injections, and Clobetasol, along with vitamin D and collagen supplements. They are considering additional treatments like minoxidil and microneedling, and there is discussion about whether the hair loss is due to stress, alopecia areata, or a scarring condition like lichen planopilaris.

A 20-year-old male has been experiencing hair loss since age 15-16 and is using oral minoxidil, dutasteride, and ketoconazole shampoo, with previous use of oral finasteride and topical minoxidil. He has stabilized hair loss but seeks to rule out inflammatory or immune-related causes, considering a scalp biopsy, and is supplementing with vitamin D3, B12, and iron.